Martin Yang, Oppenheimer senior analyst, joins 'Squawk on the Street' to discuss what Apple Intelligence is lacking that's ...
Baird downgraded Leap Therapeutics (LPTX) to Neutral from Outperform with a price target of $1.25, down from $9, after the ...
Investors were hoping that Apple Intelligence would drive a wave of iPhone upgrades. How's that playing out? This will be the first full quarter of results from Apple since the company's iPhone 16 ...
Shares of Apple have surged roughly 40% over the past nine months, but one analyst issued a cautious warning that it’s time to tap the brakes ahead of the company’s earnings report set for Thursday.